Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Zevra Therapeutics (NasdaqGS: ZVRA), a commercial-stage rare disease therapy company, announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's executive team will engage in a fireside chat on August 13, 2025, at 1:00 p.m. ET in Boston, MA.
Management will also be available for one-on-one meetings with registered attendees. Investors can access the live webcast through the "Events & Presentations" section on Zevra's investor relations website at investors.zevra.com.
Zevra Therapeutics (NasdaqGS: ZVRA), un'azienda in fase commerciale specializzata in terapie per malattie rare, ha annunciato la sua partecipazione alla 45陋 Conferenza Annuale sulla Crescita di Canaccord Genuity. Il team esecutivo della societ脿 parteciper脿 a un incontro informale il 13 agosto 2025 alle 13:00 ET a Boston, MA.
La direzione sar脿 inoltre disponibile per incontri individuali con i partecipanti registrati. Gli investitori potranno seguire la diretta streaming nella sezione "Eventi e Presentazioni" sul sito delle relazioni con gli investitori di Zevra all'indirizzo investors.zevra.com.
Zevra Therapeutics (NasdaqGS: ZVRA), una empresa en etapa comercial dedicada a terapias para enfermedades raras, anunci贸 su participaci贸n en la 45陋 Conferencia Anual de Crecimiento de Canaccord Genuity. El equipo ejecutivo de la compa帽铆a participar谩 en una charla informal el 13 de agosto de 2025 a la 1:00 p.m. ET en Boston, MA.
La gerencia tambi茅n estar谩 disponible para reuniones individuales con los asistentes registrados. Los inversores pueden acceder a la transmisi贸n en vivo a trav茅s de la secci贸n "Eventos y Presentaciones" en el sitio web de relaciones con inversionistas de Zevra en investors.zevra.com.
Zevra Therapeutics (NasdaqGS: ZVRA)電� 靸侅梾 雼硠鞚� 頋穩 歆堩櫂 旃橂 須岇偓搿滌劀 雼り皜鞓る姅 Canaccord Genuity 鞝�45須� 鞐半 靹膘灔 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 瓴届榿歆勳潃 2025雲� 8鞗� 13鞚� 鞓ろ泟 1鞁�(霃欕秬 鞁滉皠), 毵れ偓於旍劯旄犾＜ 氤挫姢韯挫棎靹� 歆勴枆霅橂姅 靻岅窚氇� 雽�頇旍棎 彀胳劃頃� 鞓堨爼鞛呺媹雼�.
瓴届榿歆勳潃 霌彪霅� 彀胳劃鞛愲摛瓿检潣 鞚茧寑鞚� 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� Zevra 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞚� "鞚措菠韸� 氚� 頂勲爤鞝犿厡鞚挫厴" 靹轨厴鞚� investors.zevra.com鞐愳劀 霛检澊敫� 鞗轨簮鞀ろ姼毳� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Zevra Therapeutics (NasdaqGS : ZVRA), une entreprise en phase commerciale sp茅cialis茅e dans les th茅rapies pour maladies rares, a annonc茅 sa participation 脿 la 45e Conf茅rence Annuelle sur la Croissance de Canaccord Genuity. L'茅quipe dirigeante de la soci茅t茅 participera 脿 une discussion informelle le 13 ao没t 2025 脿 13h00 ET 脿 Boston, MA.
La direction sera 茅galement disponible pour des r茅unions individuelles avec les participants inscrits. Les investisseurs peuvent acc茅der 脿 la diffusion en direct via la section 芦 脡v茅nements & Pr茅sentations 禄 sur le site des relations investisseurs de Zevra 脿 investors.zevra.com.
Zevra Therapeutics (NasdaqGS: ZVRA), ein Unternehmen im kommerziellen Stadium f眉r Therapien seltener Krankheiten, gab seine Teilnahme an der bevorstehenden 45. j盲hrlichen Wachstumskonferenz von Canaccord Genuity bekannt. Das F眉hrungsteam des Unternehmens wird an einem Fireside-Chat am 13. August 2025 um 13:00 Uhr ET in Boston, MA, teilnehmen.
Das Management steht auch f眉r Einzelgespr盲che mit registrierten Teilnehmern zur Verf眉gung. Investoren k枚nnen den Live-Webcast 眉ber den Bereich "Events & Presentations" auf der Investor-Relations-Website von Zevra unter investors.zevra.com verfolgen.
- None.
- None.
CELEBRATION, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra鈥檚 executive leadership team will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, on Wednesday, August 13, 2025, at 1:00 p.m. ET.
Additionally, management will be available for one-on-one meetings with registered conference attendees. The live webcast will be accessible via 鈥溾�� on the Investor Relations section of Zevra鈥檚 website at .听
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
For more information, please visit or follow us on and .
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra鈥檚 participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra鈥檚 Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, and Zevra鈥檚 Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 13, 2025, and Zevra鈥檚 other filings with the SEC. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.听听
Zevra Contact
Nichol Ochsner听
+1 (732) 754-2545听
听听
FAQ
When is Zevra Therapeutics (ZVRA) presenting at the Canaccord Genuity Conference?
How can investors watch Zevra's (ZVRA) Canaccord conference presentation?
What type of presentation will Zevra (ZVRA) give at the Canaccord conference?
Will Zevra (ZVRA) management be available for individual meetings at the conference?
